These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 18289006)
1. Self-adjuvanting lipopeptide vaccines. Moyle PM; Toth I Curr Med Chem; 2008; 15(5):506-16. PubMed ID: 18289006 [TBL] [Abstract][Full Text] [Related]
2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
3. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. Zeng W; Ghosh S; Lau YF; Brown LE; Jackson DC J Immunol; 2002 Nov; 169(9):4905-12. PubMed ID: 12391202 [TBL] [Abstract][Full Text] [Related]
4. Method for the synthesis of highly pure vaccines using the lipid core peptide system. Moyle PM; Olive C; Good MF; Toth I J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293 [TBL] [Abstract][Full Text] [Related]
5. Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery. Bartlett S; Skwarczynski M; Toth I Curr Med Chem; 2020; 27(17):2887-2901. PubMed ID: 30362416 [TBL] [Abstract][Full Text] [Related]
6. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036 [TBL] [Abstract][Full Text] [Related]
7. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population. Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096 [TBL] [Abstract][Full Text] [Related]
8. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Moyle PM Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861 [TBL] [Abstract][Full Text] [Related]
9. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Skwarczynski M; Toth I Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338 [TBL] [Abstract][Full Text] [Related]
10. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764 [TBL] [Abstract][Full Text] [Related]
11. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288 [TBL] [Abstract][Full Text] [Related]
13. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Huang W; Nardelli B; Tam JP Mol Immunol; 1994 Oct; 31(15):1191-9. PubMed ID: 7935506 [TBL] [Abstract][Full Text] [Related]
14. Lipid-based self-adjuvanting vaccines. Brown LE; Jackson DC Curr Drug Deliv; 2005 Oct; 2(4):383-93. PubMed ID: 16305441 [TBL] [Abstract][Full Text] [Related]
15. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype. McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324 [TBL] [Abstract][Full Text] [Related]
17. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo. Sauzet JP; Moog C; Krivine A; Martinon F; Bossus M; Gras-Masse H; Tartar A; Guillet JG; Gomard E AIDS Res Hum Retroviruses; 1998 Jul; 14(10):901-9. PubMed ID: 9671219 [TBL] [Abstract][Full Text] [Related]
19. A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Zeng W; Azzopardi K; Hocking D; Wong CY; Robevska G; Tauschek M; Robins-Browne RM; Jackson DC Vaccine; 2012 Jul; 30(32):4800-6. PubMed ID: 22634295 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Chua BY; Zeng W; Jackson DC Methods Mol Biol; 2008; 494():247-61. PubMed ID: 18726578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]